Medical technology company Phase Holographic Imaging (PHI) announced on Tuesday that it is advancing its next-generation live cell imaging system to the final development stage.
The new HoloMonitor CellSync model is undergoing pre-production testing at the Huntsman Cancer Institute and Wake Forest Institute of Regenerative Medicine. This system represents the first in a series aimed at establishing a new standard in automated quality control for cell and gene therapy manufacturing. Future models will integrate cutting-edge image processing and artificial intelligence technologies.
Manufactured according to ISO 9001 standards, the HoloMonitor CellSync enhances PHI's imaging technology with a new camera module and improved automated cell segmentation. These advancements have been refined over the past two years. The HoloMonitor CellSync is slated for release in the second half of 2025.
PHI advances Next-Generation HoloMonitor CellSync for cell and gene therapy
Gan & Lee doses first participant in Phase 2 clinical trial of bofanglutide injection
Clario agrees to acquire WCG's eCOA business
Health Canada approves Johnson & Johnson therapy for advanced EGFR-mutated lung cancer
Polarean expands Xenon MRI imaging for pharma-sponsored research
Immunome initiates Phase 1 trial of ROR1-targeted ADC IM-1021
Arrowhead Pharmaceuticals reports positive topline results for ARO-C3 in IgA nephropathy trial
Celltrion's OMLYCLO receives US FDA approval
RiboX Therapeutics doses first patient in RXRG001 first-in-human Phase I/IIa clinical trial
Doer Bio completes DR10624phase two clinical study enrolment
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Kancera and Recardio sign letter of intent for licensing agreement
Bantam Pharmaceutical expands Phase 1 trial of BTM-3566 into Canada
Integral Molecular reports first patient dosed in CTIM-76 Phase 1 clinical trial